Diagnosis and management of primary aldosteronism: An updated review

References

• Conn J. Presidential address. Part II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:6–17.
   Web of Science ®Google Scholar
• Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:3266–81.
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Yamada T, Yukimura Y. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med. 1981;141:1589–93.
   PubMed Web of Science ®Google Scholar
• Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, et al. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. J Hum Hypertens. 2005;20:129–36.
   Google Scholar
• Amar L, Plouin P-F, Steichen O. Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism. Orphanet J Rare Dis. 2010;5:9.
   Google Scholar
• Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient’s cohorts and in population-based studies - a review of the current literature. Horm Metab Res. 2012;44:157–62.
   PubMed Web of Science ®Google Scholar
• Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol. 2006;48:2293–300.
   PubMed Web of Science ®Google Scholar
• Chang HW, Chu TS, Huang HY, Chueh SC, Wu VC, Chen YM, et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab. 2007;92:1863–70.
   Google Scholar
• Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237–47.
   PubMed Web of Science ®Google Scholar
• Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89–100.
   PubMed Web of Science ®Google Scholar
• Milliez P, Girerd X, Plouin P-F, Blacher J, Safar ME, Mourad J-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243–8.
   PubMed Web of Science ®Google Scholar
• Wu VC, Lo SC, Chen YL, Huang PH, Tsai CT, Liang CJ, et al. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab. 2011;96:3175–83.
   PubMed Web of Science ®Google Scholar
• Kuo CC, Wu VC, Tsai CW, Wu KD. Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2011;12:113–22.
   Google Scholar
• Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. J Clin Endocrinol Metab. 2009;94:1191–7.
   PubMed Web of Science ®Google Scholar
• Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607–18.
   PubMed Web of Science ®Google Scholar
• Lee P-H, Wu C-J, Chen Y-C, Chen H-H. Aldosterone-producing adenoma: clinical presentation, diagnosis and outcomes of surgery in Northern Taiwan. Acta Nephrol. 2009;23:143–8.
   Google Scholar
• Omura M, Sasano H, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism. Hypertens Res. 2006;29:883–9.
   Google Scholar
• Kuo C-C, Wu V-C, Huang K-H, Wang S-M, Chang C-C, Lu C-C, et al. Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group). J Renin Angiotensin Aldosterone Syst. 2011;12:348–57.
   Google Scholar
• Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res. 2004;27: 303–10.
   PubMed Web of Science ®Google Scholar
• Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, et al. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871–8.
   PubMed Web of Science ®Google Scholar
• Rossi GP. Hyperparathyroidism, arterial hypertension and aortic stiffness: a possible bidirectional link between the adrenal cortex and the parathyroid glands that causes vascular damage? Hypertens Res. 2011;34:286–8.
   Google Scholar
• Ito Y, Takeda R, Takeda Y. Subclinical primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2012;26:485–95.
   PubMed Web of Science ®Google Scholar
• Médeau V, Moreau F, Trinquart L, Clemessy M, Wémeau J-L, Vantyghem MC, et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin Endocrinol. 2008;69:20–8.
   Google Scholar
• Fallo F, Pilon C, Urbanet R. Primary aldosteronism and metabolic syndrome. Horm Metab Res. 2012;44:208–14.
   PubMed Web of Science ®Google Scholar
• Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002; 283:H1802–10.
   PubMed Web of Science ®Google Scholar
• Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens. 2008;26: 2399–405.
   PubMed Web of Science ®Google Scholar
• Sonino N, Tomba E, Genesia ML, Bertello C, Mulatero P, Veglio F, et al. Psychological assessment of primary aldosteronism: a controlled study. J Clin Endocrinol Metab. 2011;96:E878–83.
   Google Scholar
• Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol. 2006;2:198–208.
   PubMedGoogle Scholar
• Rayner B. Primary aldosteronism and aldosterone-associated hypertension. J Clin Pathol. 2008;61:825–31.
   Google Scholar
• Seccia TM, Fassina A, Nussdorfer GG, Pessina AC, Rossi GP. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocrine Relat Cancer. 2005;12:149–59.
   PubMed Web of Science ®Google Scholar
• McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004;12:44–8.
   PubMedGoogle Scholar
• Stowasser M, Gordon RD. Primary aldosteronism: from genesis to genetics. Trend Endocrinol Metab. 2003;14:310–7.
   PubMed Web of Science ®Google Scholar
• So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens. 2005;23: 1477–84.
   Google Scholar
• Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 2008;93:3117–23.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Tauber P, Zennaro M-C, Monticone S, Lang K, Beuschlein F, et al. KCNJ5 Mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235–40.
   PubMedGoogle Scholar
• Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science.Science. 2011;331:768–72.
   PubMed Web of Science ®Google Scholar
• McEwan PE, Lindop GB, Kenyon CJ. Control of cell proliferation in the rat adrenal gland in vivo by the renin-angiotensin system. Am J Physiol Endocrinol Metab. 1996;271:E192–8.
   PubMedGoogle Scholar
• Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients. J Hypertens. 2003;21:2149–57.
   PubMed Web of Science ®Google Scholar
• Sealey JE, Laragh JH. Radioimmunoassay of plasma renin activity. Semin Nucl Med. 1975;5:189–202.
   PubMedGoogle Scholar
• Ferrari P, Shaw SG, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens. 2004;22:377–81.
   PubMed Web of Science ®Google Scholar
• Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo Study. J Clin Endocrinol Metab. 2004;89:4221–6.
   PubMed Web of Science ®Google Scholar
• Abdelhamid S, Blomer R, Hommel G, Haack D, Lewicka S, Fiegel P, et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens. 2003;16:522–30.
   Google Scholar
• Mourad J-J, Girerd X, Milliez P, Lopez-Sublet M, Lejeune S, Safar ME. Urinary aldosterone-to-active-renin ratio: a useful tool for predicting resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenomas. Am J Hypertens. 2008;21:742–47.
   PubMed Web of Science ®Google Scholar
• Bernini G, Moretti A, Orlandini C, Berti P, Miccoli P, Bardini M, et al. Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens. 2008;26:981–8.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Okuyama M, Nakagawa R, Honma S, Satoh F, Morimoto R, et al. Development of sensitive derivatization method for aldosterone in liquid chromatography–electrospray ionization tandem mass spectrometry of corticosteroids. J Chromatogr A. 2008;1200:114–21.
   PubMed Web of Science ®Google Scholar
• Chappell DL, McAvoy T, Weiss B, Weiner R, Laterza OF. Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC–MS/MS. Bioanalysis. 2012;4:2843–50.
   Google Scholar
• Taylor PJ, Gordon RD, Stowasser M. Calibrators for measuring aldosterone by liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2012;413:346–7.
   Google Scholar
• Taylor PJ, Cooper DP, Gordon RD, Stowasser M. Measurement of aldosterone in human plasma by semiautomated HPLC–tandem mass spectrometry. Clin Chem. 2009;55:1155–62.
   PubMed Web of Science ®Google Scholar
• Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. 2002;57:457–65.
   PubMed Web of Science ®Google Scholar
• Grasko JM, Nguyen HH, Glendenning P. Delayed diagnosis of primary hyperaldosteronism. BMJ. 2010;340:c2461.
   Google Scholar
• Pizzolo F, Pavan C, Corrocher R, Olivieri O. Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens. 2007;20:1334–7.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Stowasser M, Loh K-C, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045–50.
   PubMed Web of Science ®Google Scholar
• Hannemann A, Friedrich N, Lüdemann J, Völzke H, Rettig R, Peters J, et al. Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based Study of Health in Pomerania (SHIP-1). Horm Metab Res. 2010;42:392–9.
   PubMed Web of Science ®Google Scholar
• Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST. Validity of the aldosterone-renin ratio used to screen for primary aldosteronism. Mayo Clin Proc. 2001;76:877–82.
   Google Scholar
• Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension. 2001;37:1440–3.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, et al. Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension. 2007;50:e26–7.
   PubMed Web of Science ®Google Scholar
• Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf). 1992;36:499–503.
   Google Scholar
• Wu VC, Chueh SC, Chang HW, Lin WC, Liu KL, Li HY, et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM. 2008;101:13–22.
   Google Scholar
• Küpers EM, Amar L, Raynaud A, Plouin P-F, Steichen O. A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab. 2012;97:3530–7.
   Google Scholar
• Young Jr WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery. 2004;136:1227–35.
   PubMed Web of Science ®Google Scholar
• Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25:S143–58.
   Google Scholar
• Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, et al. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab. 2001;86:1083–90.
   PubMed Web of Science ®Google Scholar
• Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results. J Nucl Med. 2009;50:1631–7.
   PubMed Web of Science ®Google Scholar
• Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, et al. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab. 2012;97:100–9.
   PubMed Web of Science ®Google Scholar
• Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens. 2001;15:173–6.
   Google Scholar
• Fu B, Zhang X, Wang G-X, Lang B, Ma X, Li H-Z, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma. J Urol. 2011;185:1578–82.
   Google Scholar
• Lin Y-H, Lee H-H, Liu K-L, Lee J-K, Shih S-R, Chueh S-C, et al. Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy. Surgery. 2011;150:526–33.
   PubMed Web of Science ®Google Scholar
• Wu V-C, Kuo C-C, Wang S-M, Liu K-L, Huang K-H, Lin Y-H, et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. J Hypertens. 2011;29:1778–86.
   PubMed Web of Science ®Google Scholar
• Sywak M, Pasieka JL. Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br J Surg. 2002;89:1587–93.
   PubMed Web of Science ®Google Scholar
• Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med. 2001;135: 258–61.
   PubMed Web of Science ®Google Scholar
• Kater CE, Biglieri EG, Schambelan M, Arteaga E. Studies of impaired aldosterone response to spironolactone-induced renin and potassium elevations in adenomatous but not hyperplastic primary aldosteronism. Hypertension. 1983;5:V115–21.
   Google Scholar
• Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, Devries C, Plouin P-F, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820–5.
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Ménard J, White WB, Young WFJ, Williams GH, Williams B, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980–90.
   PubMed Web of Science ®Google Scholar
• Farquharson CAJ, Struthers AD. Spironolactone Increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–7.
   PubMed Web of Science ®Google Scholar